The chemical biology of clinically tolerated NMDA receptor antagonists

@article{Chen2006TheCB,
  title={The chemical biology of clinically tolerated NMDA receptor antagonists},
  author={Huei-Sheng Vincent Chen and Stuart A. Lipton},
  journal={Journal of Neurochemistry},
  year={2006},
  volume={97}
}
Most neuroprotective drugs have failed in clinical trials because of side‐effects, causing normal brain function to become compromised. A case in point concerns antagonists of the N‐methyl‐D‐aspartate type of glutamate receptor (NMDAR). Glutamate receptors are essential to the normal function of the central nervous system. However, their excessive activation by excitatory amino acids, such as glutamate itself, is thought to contribute to neuronal damage in many neurological disorders ranging… 
Clinically Tolerated Strategies for NMDA Receptor Antagonism
TLDR
This chapter reviews the logical process that was applied over the last decade to develop memantine as the first clinically tolerated yet effective agent against NMDAR-mediated neurotoxicity.
NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
TLDR
Open-channel blockers with uncompetitive antagonism and drugs modulating NMDAR activities are appealing therapeutic strategies because, in theory, these properties could decrease neurotoxicity due to excessive levels of glutamate while sparing physiological neurotransmission.
Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
TLDR
Novel NitroMemantines are described, comprising an adamantane moiety that binds in the NMDAR-associated ion channel that is used to target a nitro group to redox-mediated regulatory sites on the receptor and are both well tolerated and effective against cerebral infarction in rodent models.
NEUROPROTECTIVE STRATEGIES: DEVELOPMENT OF A CLINICALLY TOLERATED COMPOUND *
TLDR
It is demonstrated how compounds that act by an uncompetitive mechanism with a fast off-rate (socalled UFO drugs that quickly disappear from the target when no longer needed) can target pathologically active tissue.
Inhibition of human serine racemase, an emerging target for medicinal chemistry.
TLDR
The present literature on the activity and inhibition of mammalian SRs is summarized, approaches that have been applied to design SR inhibitors are summarized, and possible mechanisms of action for the active compounds are suggested.
Novel NMDA receptor modulators: an update
TLDR
First-in-class potentiators and subunit-selective agents form the basis for most new strategies, complemented by efforts to limit off-target liability and fine-tune on-target properties.
The Diversity of Mechanisms of Blockade of Ion Channels as a Pathway to the Design of New Pharmacological Agents
TLDR
It is suggested that only detailed study of the mechanisms of action of antagonists on glutamate receptors can bring us towards the ability to predict the results of using blockers in vivo on the basis of data obtained in vitro.
Memantine for the Treatment of Dementia: A Review on its Current and Future Applications
TLDR
The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as well as in preventing Aβ production, aggregation, or downstream neurotoxic consequences, in part through the blockade of extrasynaptic NMDAR.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 145 REFERENCES
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
TLDR
It is suggested that glutamate receptors of the N‐methyl‐D‐aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in Alzheimer's disease, and memantine would be expected to improve both symptoms (cognition) and to slow down disease progression because it takes over the physiological function of magnesium.
Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.
TLDR
This review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails and link the in vivo pharmacological investigations that led to the success/mistakes/ failures for eventual testing of promising compounds in the clinic.
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
TLDR
Channel-level factors may allow memantine to block channel activity induced by low, tonic levels of glutamate--an action that might contribute to symptomatic improvement and could theoretically protect against weak excitotoxicity--while sparing synaptic responses required for normal behavioral functioning, cognition and memory.
Mechanism of action of memantine.
Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents – toward an understanding of their favorable tolerability
TLDR
Current research attempting to explain the improved tolerability of low affinity NMDA receptor antagonists is reviewed, finding kinetic properties, particularly rapid blocking rate, seem to be of key importance.
Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
  • S. Lipton
  • Biology
    Nature Reviews Drug Discovery
  • 2006
TLDR
The molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca2+ influx through the receptor's associated ion channel and consequent free-radical formation is reviewed.
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity
  • H. Chen, J. Pellegrini, S. Lipton
  • Biology, Psychology
    The Journal of neuroscience : the official journal of the Society for Neuroscience
  • 1992
TLDR
Low micromolar concentrations of memantine, levels known to be tolerated by patients receiving the drug for the treatment of Parkinson's disease, prevent NMDA receptor-mediated neurotoxicity in cultures of rat cortical and retinal ganglion cell neurons; memantine also appears to be both safe and effective in a rat stroke model, suggesting that memantine has considerable therapeutic potential for the myriad of clinical entities associated with NMda receptor- mediated neurotoxicity.
Neuroprotection in Acute Ischaemic Stroke
TLDR
A number of drugs that are in the early stages of development, such as YM 872, Bay X 3702 and BMS 204352, appear to offer new hope for neuroprotection.
Excitatory amino acids as a final common pathway for neurologic disorders.
In many neurologic disorders, injury to neurons may be caused at least in part by overstimulation of receptors for excitatory amino acids, including glutamate and aspartate. These neurologic
...
1
2
3
4
5
...